Ligand Announces OmniAb? Partnership with Genagon Therapeutics

SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden. Under the terms of the partnership, Genagon gains access to the full OmniAb platform including OmniRat?, OmniMouse?, OmniFlic? and OmniChicken? in their drug discovery efforts. Ligand received an upfront payment and is eligible to receive development milestone payments and t

Click to view original post